Used primarily as a short-acting beta-1 selective blocker in clinical settings, especially during anesthesia and critical care. It is effective in managing acute tachyarrhythmias, particularly in patients undergoing surgery or those in intensive care. Due to its ultra-short half-life and rapid onset, it allows for precise control of heart rate without prolonged effects, making it suitable for use in unstable cardiac conditions. Commonly administered intravenously to control rapid heart rate in perioperative settings or during acute atrial fibrillation. Its high selectivity for beta-1 receptors reduces the risk of bronchoconstriction, which is beneficial in patients with respiratory conditions.